Table 2

Selected ongoing and/or recruiting clinical trials in advanced malignant tumor

TargetTrial noRegimenDiseasePhase
OX40NCT02528357GSK3174998 alone or with pembrolizumabAdvanced solid tumor1
NCT02737475BMS-986178 alone or in combination With nivolumab and/or IpilimumabAdvanced solid tumor1/2
NCT03092856Axitinib With or Without PF-04518600Metastatic kidney cancer2
NCT04198766INBRX-106 (Hexavalent OX40 Agonist) and pembrolizumabLocally advanced or metastatic solid tumor1
NCT03831295SD-101 and BMS-986178Locally advanced or metastatic solid tumor1
NCT03894618SL-279252 (PD1-Fc- OX40L)Locally advanced or metastatic solid tumor or lymphoma1
NCT03971409Avelumab with binimetinib, utomilumab or PF-04518600Stage IV or unresectable or recurrent triple negative breast cancer1
NCT03217747Avelumab, utomilumab, PF-04518600 and radiation therapyAdvanced solid tumor1/2
NCT03782467ATOR-1015 (Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and OX40)Advanced solid tumor1
NCT03447314Combination of GSK1795091 and Immunotherapies (GSK1795091Drug: GSK3174998Drug: GSK3359609Drug: pembrolizumab)Advanced solid tumor1
4-1BBNCT02845323Neoadjuvant nivolumab with and without urelumabCisplatin ineligible or chemorefractory muscle invasive urothelial carcinoma2
NCT033643484-1BB agonist monoclonal antibody PF-05082566 with trastuzumab emtansine or trastuzumabAdvanced HER2-positive breast cancer1
NCT03217747Avelumab, utomilumab, PF-04518600 (Anti OX40) and radiation therapyAdvanced solid tumor1/2
NCT04009460ES101 (PD-L1×4–1 BB bispecific antibody)Advanced solid tumor1
NCT03650348PRS-343 in combination with atezolizumabHER2-positive solid tumor1
NCT04144842ATOR-1017Advanced solid tumor1
NCT04121676AGEN2373Advanced cancer1
NCT03881488CTX-471 post-PD-1/PD-L1Locally advanced solid tumor/metastatic cancer1
GITRNCT02598960BMS-986156 alone or in combination with nivolumabAdvanced solid tumor1/2
NCT04021043MS-986156, Ipilimumab, and nivolumab with or without stereotactic body radiation therapyAdvanced or metastatic lung/chest or liver cancer1/2
NCT03799003ASP1951 with or without pembrolizumabAdvanced solid tumor1
NCT03123783APX005M in combination with nivolumabNon-small cell lung cancer and melanoma1
NCT02740270GWN323 alone and in combination with PDR001Advanced malignancies and lymphomas1
NCT03126110INCAGN01876 combined with immune therapiesLocally advanced solid tumor/metastatic cancer1/2
CD40NCT03123783APX055M in combination with nivolumabNon-small cell lung cancer/metastatic melanoma1/2
NCT02706353APX005M in combination with pembrolizumabMetastatic melanoma1/2
NCT02376699SEA-CD40Advanced malignancy1
NCT03852511NG-350A oncolytic virusMetastatic cancer1
NCT02705196LOAd704 oncolytic virusPancreatic cancer1/2
NCT03329950CDX-1140 as monotherapy or in combinationAdvanced malignancies1
ICOSNCT03989362Vopratelimab (JTX-2011) and a CTLA-4 inhibitorNon-small cell lung cancer/urothelial cancer2
NCT03219224Vopratelimab alone and in combination with anti-PD-1 or anti-CTLA-4Advanced solid tumor1/2
NCT03829501KY1044 and atezolizumabAdvanced cancer1/2
NCT02723955GSK3359609Advanced solid tumor1
NCT03693612GSK3359609 plus tremelimumabAdvanced solid tumor2